Ligand Pharmaceuticals Inc
LGNDCIK 0000886163 · last filing Jul 6, 2026
Insider signal
trades dated in the last 90 days · non-derivative only
5,281 bought / 5,000 sold
net +281 sh · −$1.26M
- buys
- 4
- sells
- 8
- insiders active
- 3
Filing tape
Filed Mon, Jul 6, 2026
- +132 sh · $1.28M
Reardon Andrew — CLO & Secretary
- Acquired132Common Stock@ $160.71→ 41,514 held
- Exercised5,000Common Stock@ $52.27→ 46,514 held
- Sold396Common Stock@ $308.99→ 46,118 held
- Sold104Common Stock@ $310.20→ 46,014 held
- Sold1,119Common Stock@ $311.72→ 44,895 held
- Sold1,081Common Stock@ $312.28→ 43,814 held
- Sold700Common Stock@ $313.46→ 43,114 held
- Sold100Common Stock@ $314.58→ 43,014 held
- Sold900Common Stock@ $315.78→ 42,114 held
- Sold600Common Stock@ $317.15→ 41,514 held
- Exercised5,000Employee Stock Option (right to buy)→ 34,444 held
- +17 sh · $2.7K
Espinoza Octavio — Chief Financial Officer
- Acquired17Common Stock@ $160.71→ 27,696 held
- +132 sh · $21.2K
Davis Todd C — Chief Executive Officer · Director
- Acquired132Common Stock@ $160.71→ 199,513 held
Insiders on this tape
- Reardon AndrewCLO & Secretary
- Espinoza OctavioChief Financial Officer
- Davis Todd CChief Executive Officer · Director
Informational data only — not investment advice.
The institutional holdings shown here are aggregated from third-party public regulatory filings (such as SEC Form 13F). These filings are reported with a delay (generally up to 45 days after each quarter-end), are backward-looking, and may exclude short positions, non-U.S. holdings, cash, and other assets. The data may contain errors, omissions, misclassifications, or gaps, and may not reflect a manager's current positions.
All figures are provided on an "as is" basis for general information only. Nothing on this page is financial, investment, or trading advice, a recommendation, or an endorsement of any security, manager, or strategy. Do not rely on it. Independently verify any figure against the original filings and consult a qualified professional before making any financial decision. Your use is subject to our Terms of Service.